Form **8937**(December 2017) Department of the Treasury Internal Revenue Service

Report of Organizational Actions Affecting Basis of Securities

► See separate instructions.

OMB No. 1545-0123

Part I Reporting Issuer						
1 Issuer's name	2 Issuer's employer identification number (EIN)					
PDL BioPharma, Inc.	94-3023969					
3 Name of contact for additional information	4 Telephone No. of contact	5 Email address of contact				
Edward Imbrogno	edward.imbrogno@pdl.com					
6 Number and street (or P.O. box if mail is n	7 City, town, or post office, state, and ZIP code of contact					
932 Southwood Boulevard	Incline Village, NV 89451					
8 Date of action	9 Classification and description					
October 1, 2020	Conversion Rate Adjustment on Conve	ertible Debt				
10 CUSIP number 11 Serial number	er(s) 12 Ticker symbol	13 Account number(s)				
69329YAJ3 69329YAG9	ach additional statements if needed. See b	assist of form for additional quantions				
Control of the Property of the		gainst which shareholders' ownership is measured for				
		ue 2021 and 2024 (the "Notes"), PDL Biopharma, Inc.				
	Notes as a result of PDL's distribution of its					
	reased from 316.5801 per Note to 410.6268 pe					
Stock Holders. The conversion rate was med	cased from 6 to odd i per mote to 410.0200 pe	Note on October 1, 2020.				
The value of the conversion rate adjustmen	t was calculated to be \$302.83 per Note.					
The value of the conversion rate department						
		The state of the s				
15 Describe the quantitative effect of the or	ganizational action on the basis of the security	in the hands of a U.S. taxpayer as an adjustment per				
The state of the s	PDL does not expect the Note conversion ra					
		the distribution of Lensar to its common stock				
		In addition, (1) other than the distribution of Evofem				
		331, no other distributions with respect to PDL				
		PDL stock are intended to constitute liquidating				
		treated as receiving a taxable dividend, and are not				
expected to have a basis adjustment in their Notes as a result of the Note conversion rate adjustment.						
16 Describe the calculation of the change in	basis and the data that supports the calculation	on, such as the market values of securities and the				
valuation dates ► Holders of the Notes	are not expected to have a basis adjustment	as a result of the Note conversion rate adjustment.				

Part I		Organizational Action (continu	ied)		
		applicable Internal Revenue Code see		which the tax treatment is ba	ased ►
Internal	Reve	enue Code Sections 301, 305, 331 ar	nd 6045B		

	-				
18 Ca	an any	y resulting loss be recognized? ► No	loss may be recognized		
	C .				
19 Pr	ovide	any other information necessary to in	nplement the adjustment, such a	s the reportable tax year ▶	For calendar year tax payers, the
reportin	g per	riod is the tax year ending December	r 31, 2020.		
-					
includin	g the				on rate adjustments described above, tion set forth in this document does

	Unde	er penalties of perjury, I declare that I have	examined this return, including acco	empanying schedules and state	ments, and to the best of my knowledge and
	belief	f, it is true, correct, and complete. Declarati	on of preparer (other than officer) is b	ased on all information of which	n preparer has any knowledge.
Sign Here	Signa	ature Elward O. Am	bugno	Date ▶/.	2/2/2020
		/	0		1050
	Print	your name ► Edward A. Imbrogno Print/Type preparer's name	Preparer's signature	Title ► VP a	and CFO
Paid		Fill Type preparer s fiame	Toparor o dignaturo	Date	Check if self-employed
Prepa		Firm's name ▶			Firm's EIN ▶
Use O	nly	Firm's name ► Firm's address ►			Phone no.
Send Fo	rm 89	937 (including accompanying stateme	nts) to: Department of the Treasu	ıry, Internal Revenue Service	